Overview

Randomized Study for the Assessment of Silibinin (Legalon® SIL) in the Treatment of naïve Genotype 4 Patients With Chronic Hepatitis C

Status:
Withdrawn

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore whether silibinin plus ribavirin with/without peg-interferon can be more effective than the peg-interferon plus ribavirin based standard of care (SoC) in the treatment of patients infected with hepatitis C virus genotype 4.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Rottapharm

Treatments:

Interferon alpha-2
Interferon-alpha
Interferons
Peginterferon alfa-2b
Ribavirin
Silybin
Silymarin